Ischaemic stroke remains one of the leading causes of long-term disability worldwide, frequently producing debilitating vascular cognitive impairment. Addressing post-stroke cognitive decline is critical because progressive intellectual and functional deterioration substantially degrades patient autonomy and escalates the healthcare burden. While standard secondary prevention typically emphasizes antiplatelet therapy, blood pressure management, and lipid control, targeted pharmacological interventions to preserve cognitive networks remain scarce. DL-3-n-butylphthalide, a synthetic multi-target compound originally derived from celery seed extract, has demonstrated notable neurovascular protective effects in acute stroke models and short-term trials. Consequently, clinicians require robust long-term evidence to determine whether sustained butylphthalide therapy confers lasting cognitive neuroprotection during the convalescent rehabilitation phase.

The Growing Burden of Post-Stroke Cognitive Decline

Cognitive impairment after cerebral infarction affects a substantial proportion of survivors, frequently presenting within weeks to months following the index vascular event. Vascular cognitive deficits alter executive functioning, processing speed, spatial orientation, and complex language comprehension. Furthermore, post-stroke cognitive impairment severely impedes physical neurorehabilitation, reduces compliance with secondary prevention regimens, and increases institutionalization rates. Traditional therapeutic strategies focus on mitigating recurrence risks, yet they often fail to address chronic microvascular hypoperfusion, persistent neuroinflammation, and secondary neurodegeneration in peri-infarct tissue. Therefore, identifying neuroprotective agents capable of interrupting long-term neurovascular unit breakdown represents an urgent clinical priority. Sustained therapeutic intervention during the subacute to chronic transition window offers a viable opportunity to preserve neuronal integrity and stabilize functional independence in vulnerable stroke survivors.

Study Design and Evaluation of Butylphthalide

To evaluate the long-term clinical utility of butylphthalide, investigators conducted a rigorous prospective follow-up study over a 12-month observation window. The study enrolled patients who had newly diagnosed ischaemic stroke between one and six months prior, specifically targeting individuals beyond the hyperacute phase. Researchers assigned participants to either an active butylphthalide treatment cohort or a standard control group. Clinicians systematically tracked cognitive function using the validated Mini-Mental State Examination at baseline and at the 12-month mark. In addition, the research team performed multivariate regression analyses, t-tests, and chi-square evaluations to adjust for baseline confounding variables. By focusing on patients during the subacute rehabilitation window, the study design isolated the prolonged neuroprotective influence of butylphthalide on ongoing cognitive performance.

Key Findings and Cognitive Score Preservation

The 12-month results revealed that butylphthalide administration significantly halted cognitive deterioration compared to standard care. Specifically, multivariate regression confirmed that butylphthalide was inversely associated with the absolute Mini-Mental State Examination score change (β = -0.122; 95% CI -1.932 to -0.298; p = 0.003) and the percentage decline in cognitive scores (β = -0.117; 95% CI -0.057 to -0.011; p = 0.004). Moreover, treated patients exhibited a markedly reduced overall incidence of cognitive decline (odds ratio = 0.612; p = 0.020). Detailed subscale analyses demonstrated pronounced therapeutic benefits in orientation and language domains. Thus, sustained butylphthalide treatment effectively stabilized overall mental status, mitigating the progressive neurocognitive decline frequently observed in convalescent stroke survivors.

Mechanisms Mitigating Post-Stroke Cognitive Decline

The biological mechanisms underlying the clinical benefits of butylphthalide involve multiple synergistic pathways across the neurovascular unit. Experimental and clinical pharmacological studies indicate that butylphthalide enhances cerebral microcirculation and stimulates collateral vessel formation, thereby improving peri-infarct perfusion. In addition, the molecule preserves mitochondrial integrity, prevents adenosine triphosphate depletion, and downregulates excessive reactive oxygen species production. By inhibiting nuclear factor-kappa B signaling, butylphthalide attenuates neuroinflammatory cascades and reduces microglial hyperactivation. Furthermore, it upregulates key neurotrophic factors, including brain-derived neurotrophic factor and vascular endothelial growth factor. Consequently, these synchronized cytoprotective actions prevent secondary axonal loss, preserve synaptic plasticity, and protect vulnerable neural circuits from chronic ischemic damage.

Clinical Risk Factors and High-Risk Subpopulations

The prospective study also highlighted critical demographic and clinical predictors that heighten susceptibility to cognitive deterioration after stroke. Advanced age of 60 years or older emerged as an independent risk factor for accelerated cognitive deterioration. Similarly, lower educational attainment correlated strongly with reduced baseline cognitive reserve and greater 12-month score deterioration. Patients possessing these high-risk characteristics experienced faster functional decline without neuroprotective therapy. Therefore, clinicians must implement early cognitive screening protocols tailored to elderly and educationally vulnerable stroke survivors. Recognizing these distinct risk profiles enables physicians to stratify patients accurately and initiate targeted neurovascular protective therapies before irreversible cognitive deficits become established.

Translating Evidence into Post-Stroke Neurorehabilitation

Integrating butylphthalide into comprehensive post-stroke management regimens represents a promising development for long-term stroke rehabilitation protocols. Because physical and cognitive recovery are intrinsically connected, preserving mental processing directly enhances functional independence and daily living activities. Clinicians should consider incorporating neuroprotective pharmacotherapy alongside speech therapy, physical rehabilitation, and metabolic risk factor control. However, physicians must evaluate patient-specific factors, monitor treatment adherence, and maintain vigilance regarding potential drug interactions. As global healthcare systems face escalating dementia and stroke burdens, adopting proven neuroprotective strategies offers a practical pathway to optimize recovery outcomes and enhance quality of life for stroke survivors.

Frequently Asked Questions (FAQs)

How does butylphthalide reduce post-stroke cognitive decline?

Butylphthalide enhances microvascular circulation, promotes collateral vessel growth, protects mitochondrial function, and suppresses chronic neuroinflammation. These combined actions preserve peri-infarct brain tissue, support synaptic plasticity, and prevent progressive neuronal damage, ultimately stabilizing orientation, memory, and language functions over time.

Which patient groups are at highest risk for post-stroke cognitive impairment?

Patients aged 60 years or older and individuals with lower baseline educational attainment face significantly higher risks of post-stroke cognitive deterioration. These high-risk groups exhibit reduced cognitive reserve and require proactive cognitive surveillance alongside early, targeted neuroprotective interventions.

When should neuroprotective therapy be initiated during stroke recovery?

Evidence demonstrates significant cognitive preservation when clinicians initiate neuroprotective therapy during the subacute window, between one and six months post-stroke onset. Starting treatment during this convalescent period helps counteract ongoing microvascular hypoperfusion and secondary neurodegeneration during active rehabilitation.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Healthcare professionals must exercise their independent clinical judgment when evaluating patient care strategies. Refer to the latest local and national guidelines for clinical practice.

References

1. Han Q et al. Efficacy of butylphthalide in preventing cognitive decline in ischaemic stroke survivors: a 12-month prospective following-up study. Stroke Vasc Neurol. 2025 Oct 27. doi: 10.1136/svn-2024-003611. PMID: 39863299.
2. Wang A, Jia B, Zhang X, Huo X, Chen J, Gui L, et al. Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial. JAMA Neurol. 2023;80(8):851–859.
3. Rost NS, Brodtmann A, Pase MP, van Veluw SJ, Biffi A, Duering M, et al. Post-stroke cognitive impairment and dementia. Circ Res. 2022;130(8):1252–1271.